Chemical compounds studied in this article: Alphaxalone Etomidate Pentobarbital Propofol R-5-allyl-1-methyl-5-(m-trifluoromethyldiazirynylphenyl) barbituric acid (R-mTFD-MPAB) S-1-methyl-5-propyl-5-(mtrifluoromethyl-diazirynylphenyl) barbituric acid (S-mTFD-MPPB) Tetrahydrodeoxycorticosterone (THDOC) Keywords: ␣␤␦ ␣␤␥ GABA A receptors Allosteric modulation Concatemers General anesthetics a b s t r a c t GABA A receptors play a dominant role in mediating inhibition in the mature mammalian brain, and defects of GABAergic neurotransmission contribute to the pathogenesis of a variety of neurological and psychiatric disorders. Two types of GABAergic inhibition have been described: ␣␤␥ receptors mediate phasic inhibition in response to transient high-concentrations of synaptic GABA release, and ␣␤␦ receptors produce tonic inhibitory currents activated by low-concentration extrasynaptic GABA. Both ␣␤␦ and ␣␤␥ receptors are important targets for general anesthetics, which induce apparently different changes both in GABA-dependent receptor activation and in desensitization in currents mediated by ␣␤␥ vs. ␣␤␦ receptors. Many of these differences are explained by correcting for the high agonist efficacy of GABA at most ␣␤␥ receptors vs. much lower efficacy at ␣␤␦ receptors. The stoichiometry and subunit arrangement of recombinant ␣␤␥ receptors are well established as ␤-␣-␥-␤-␣, while those of ␣␤␦ receptors remain controversial. Importantly, some potent general anesthetics selectively bind in transmembrane inter-subunit pockets of ␣␤␥ receptors: etomidate acts at ␤ + /␣ − interfaces, and the barbiturate R-5-allyl-1-methyl-5-(m-trifluoromethyl-diazirynylphenyl) barbituric acid (R-mTFD-MPAB) acts at ␣ + /␤ − and ␥ + /␤ − interfaces. Thus, these drugs are useful as structural probes in ␣␤␦ receptors formed from free subunits or concatenated subunit assemblies designed to constrain subunit arrangement. Although a definite conclusion cannot be drawn, studies using etomidate and R-mTFD-MPAB support the idea that recombinant ␣1␤3␦ receptors may share stoichiometry and subunit arrangement with ␣1␤3␥2 receptors.
Introduction
␥-Aminobutyric acid type A (GABA A ) receptors are major mediators of inhibition in the CNS [1, 2] . The GABA A receptor is a chloride ion channel, a member of the pentameric Cys-loop superfamily of ligand-gated ion channels (pLGICs), which also include nicotinic acetylcholine, glycine, 5-HT 3 and zinc-activated receptors [3] . Multiple GABA A receptor subunit subtypes and splice variants have been identified: ␣1-␣6, ␤1-␤3, ␥1-␥3, ␦, , , and 1-3 [4, 5] . Each subunit is composed of a N-terminal extracellular hydrophilic domain, four transmembrane ␣-helices (M1-M4), three inter-helix loops, and a C-terminal extracellular domain [6, 7] . GABA A receptors mostly consist of two ␣ subunits, two ␤ subunits and one additional subunit from either a ␥ or ␦ [4] . The composition, stoichiometry and subunit arrangement of receptors containing , and are unknown. The predominant GABA A receptor isoforms in the brain are ␣␤␥ and ␣␤␦ [8] . ␣␤␥ receptors, with ␣1␤2␥2 as the most common isoform, are widely distributed in the brain [8, 9] and at the cellular level are mostly localized in synapses [10, 11] , although ␣5␤␥ receptors [12] [13] [14] and a small fraction of other ␣␤␥ receptors are also extrasynaptic [10, 11] . In contrast, ␣␤␦ receptors only constitute a small proportion of GABA A receptors in the brain [8, 15] and at the cellular level are located outside of synapses [10, 16] . The ␦ subunits co-assemble with ␣6 subunits in the cerebellum [17] [18] [19] and with ␣4 subunits in the hippocampus, striatum, thalamus and cortex [19] [20] [21] [22] [23] . Co-assembly of ␦ and ␣1 subunits is observed in the hippocampus [24] . Although ␣1 and ␦ subunit mRNAs are found in the thalamus [25] , co-immunoprecipitation of ␣1 and ␦ subunit protein is undetectable in this brain structure [21] . The most common isoform of ␦ subunit-containing GABA A receptors in the CNS is the ␣4␤␦ receptor [8] .
Structural models of heteropentameric GABA A receptors ( Fig. 1 ) are based on high-resolution structural data from snail Lymnaea stagnalis acetylcholine binding protein [26] , bacterial and nematode homomeric pLGICs, including Gloeobacter violaceus ion channel (GLIC) [27, 28] , Erwinia chrysanthemi ion channel (ELIC) [29, 30] and Caenorhabditis elegans glutamate-gated chloride channel ␣ (GluCl) [31, 32] , a human GABA A homomeric ␤3 receptor [33] and a zebrafish ␣1 glycine receptor [34] . The interfacial surfaces of each subunit are denoted as minus (−) and plus (+) viewed from above and scanning anticlockwise. There are two GABA binding sites on typical synaptic ␣␤␥ GABA A receptors, each located in extracellular domains between ␣ and ␤ subunits (␤ + /␣ − interfaces) [35] . GABA binding induces a series of conformational changes that propagates to transmembrane domains, leading to opening of the channel gate [36] .
GABA A receptor-mediated inhibition is both phasic and tonic ( Fig. 2A) [11, 37] . Phasic inhibition is evoked by transient activation of synaptic GABA A receptors in response to brief high concentrations of GABA. Voltage-clamp recordings of neuronal inhibitory postsynaptic currents (IPSCs) measure the amplitude and kinetic properties of phasic currents. In contrast, tonic inhibition is mediated by extrasynaptic GABA A receptors, which are continuously activated by slowly varying low concentrations of ambient GABA [11, [37] [38] [39] [40] . These steady-state tonic currents are measured in voltage-clamped neurons as the holding current that is blocked by GABA A receptor antagonists such as bicuculline or picrotoxin. Tonic inhibition plays a critical role in modulating neuronal excitability in many brain areas. For example, in thalamus and hippocampus, tonic currents account for ∼75-90% of total GABA A receptor-mediated inhibitory currents [37, 41, 42] .
Evaluating the properties of individual GABA A receptor isoforms is carried out by heterologous expression of specific subunits in cells such as human embryonic kidney (HEK) cells and Xenopus oocytes. To mimic fast IPSCs and study fast components of receptor mediated currents, small cells are selected or macropatches are pulled from cell membranes, and a rapid solution-switching device (exchange times range from hundreds of sec to several msec) is used to apply agonists and/or drugs [43, 44] . This "artificial synapse" approach assesses rates of fast current phases such as desensitization (current reduction during agonist application) and deactivation (current return to baseline after terminating agonist application) [7] . Pseudo steady-state GABA A receptor responses are investigated using relatively slow solution exchange devices (solution exchange time >10 msec) in HEK cells and larger cells [45, 46] . In classical GABA concentration-response analysis, GABA EC 50 (the GABA concentration that elicits 50% of maximal response) and Hill slope, a coefficient that may give information on the number of GABA interacting sites [47] , are measured.
GABA A receptors are allosterically modulated by a myriad of compounds. Widely used positive GABA A receptor modulators include benzodiazepines, general anesthetics, and some anticonvulsants [6] . Inhibitors such as bicuculline, picrotoxin, gabazine and other convulsants, are mostly used as research tools. This review focuses on potent general anesthetics.
A variety of approaches have been used to locate and study general anesthetic sites on heteromeric GABA A receptors, including photolabeling, mutagenesis, subunit chimeras and concatenated subunit assemblies. Receptor labeling with photoreactive anesthetic analogs has identified several binding sites on ␣1␤2/3␥2 GABA A receptors [35] . Mutant studies have helped define the functional roles of amino acid residues on GABA A receptors [48] . Chimeric subunits constructed with complementary portions of subunit isoforms associated with different pharmacological sensitivity to anesthetics can identify subunit domains of interest [49] . Concatenated subunit assemblies are formed by tethering two or three subunits together using amino acid linkers to constrain subunit arrangement [50] .
Structure and function of synaptic ␣␤␥ GABA A receptors
The stoichiometry and subunit arrangement of recombinant ␣␤␥ receptors have been well established as ␤-␣-␥-␤-␣ (counterclockwise viewed from the extracellular space) (Fig. 3A ) [51] [52] [53] . Mutation of the conserved M2-9 leucine to serine (L9 S) on ␣1, ␤2 or ␥2 subunits induces a large reduction in GABA EC 50 . [179] . (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.).
Fig. 2.
Anesthetic effects on synaptic vs. extrasynaptic neuronal GABAergic currents. Panel A depicts a GABAergic synapse with a presynaptic neuron on the left and a postsynaptic neuron on the right. In response to action potentials triggering calcium influx and increased intracellular calcium in presynaptic boutons, GABA release into the synapse transiently reaches millimolar concentrations that activate most of the nearby postsynaptic GABA A receptors. Transporter-mediated reuptake into neurons rapidly reduces synaptic GABA, resulting in postsynaptic receptor deactivation. Together, these events generate inhibitory postsynaptic currents (IPSCs; panel B, top left). In the presence of anesthetic drugs, receptor deactivation and IPSC decay is slowed (panel B, top right), increasing GABA-dependent chloride flux, and reducing GABA EC50 (panel B, bottom). GABA leakage from synapses activates extrasynaptic GABA A receptors (panel A, lower right), generating tonic currents (panel C, top left). In the presence of anesthetics, tonic currents increase (panel C, top right). Because GABA is a weak agonist at extrasynaptic receptors containing ␦-subunit, anesthetics induce smaller "leftward shifts" and larger "upward shifts" in concentration-response experiments of these receptors (panel C, bottom). [51] [52] [53] , which is also illustrated in Fig. 1B, C . B, Our data in oocytes using MWC model analysis support the idea that the subunit arrangement of ␣1␤3␦ receptors is ␤3-␣1-␦-␤3-␣1 [46] , which was also proposed by Kaur et al. [76] . C, D, The other two subunit arrangements proposed by Kaur et al. [76] are ␤3-␣1-␦-␣1-␤3 and ␣1-␤3-␣1-␤3-␦. E, F, Photolabeling studies indicate that the possible subunit arrangement of ␣4␤3␦ receptors stably expressed in HEK293 cells is either ␤3-␤3-␦-␤3-␣4 or ␤3-␤3-␣4-␦-␣4 (all cartoons counterclockwise viewed from the extracellular space.).
Co-expression of receptor messenger RNAs encoding mixtures of wild type and L9 S mutant ␣1, ␤2, or ␥2 subunits produced mixed populations of receptors and multi-phasic GABA concentration-responses [51] . From the number of phases in such concentration-response curves, it was inferred that ␣1␤2␥2 receptors contain two ␣1, two ␤2 and one ␥2 subunits [51] . Baumann et al. examined the subunit arrangement of ␣1␤2␥2 receptors by co-expressing concatenated subunit assemblies that constrain different subunit arrangements [54] . Electrophysiological studies demonstrated that the subunit arrangement of ␤2-␣1-␥2-␤2-␣1 exhibits pharmacological properties similar to ␣1␤2␥2 receptors assembled from free subunits [54] . Biochemical and fluorescence energy transfer experiments [52, 53] support this stoichiometry and subunit arrangement of ␣1␤2/3␥2 receptors.
Most recombinant ␣␤␥ receptors exhibit very infrequent spontaneous gating [55] [56] [57] . It is estimated, for instance, that only about 1 in 20,000 channels is spontaneously open in ␣1␤2␥2 receptors [57] . Maximally GABA-activated (at 1-10 mM) peak currents in oocyte-expressed ␣1␤2/3␥2 receptors are enhanced about 10-20% with addition of positive allosteric modulators [38, [58] [59] [60] , indicating that GABA alone activates about 85% of the receptors. Both receptor desensitization and deactivation apparently contribute to shaping IPSC time course [61] . Receptor desensitization in ␣1␤2/3␥2, ␣4␤3␥2, ␣5␤3␥2 or ␣6␤3␥2 receptors displays multiple exponential components during prolonged GABA exposure [49, [62] [63] [64] [65] [66] [67] . Receptor desensitization reduces the speed of deactivation (desensitization-deactivation coupling) [43] in ␣1␤2/3␥2, ␣4␤3␥2, ␣5␤3␥2 or ␣6␤3␥2 receptors [65, [67] [68] [69] .
Co-expression of ␣1, ␤2 and ␥2 subunits in oocytes or HEK cells could form a mixture of ␣1␤2 and ␣1␤2␥2 receptors. In oocytes, increasing the ratio of ␥2 subunit mRNA/cDNA relative to ␣1 and ␤2 subunits (up to 10:1:1) facilitated the formation of more homogenous ␣1␤2␥2 receptors [70, 71] . In contrast, in HEK cells, reduced ratio of ␥2 subunit cDNA to ␣1 and ␤2 subunits (0.3:1:1) led to homogenous ␣1␤2␥2 receptors, while higher ␥2:␣1/␤2 ratios may result in incorporation of more than one ␥2 subunit per receptor [72] . It is currently unknown how receptor assembly differs in various cell types. However, co-expression of concatenated subunit assemblies appears to constrain subunit stoichiometry and arrangement in ␣␤␥ receptors [54, [72] [73] [74] .
Structure and function of extrasynaptic ␣␤␦ GABA A receptors
The stoichiometry and subunit arrangement of ␣␤␦ GABA A receptors is uncertain. Several approaches that were used to investigate ␣␤␥ subunit stoichiometry and arrangement were unsuccessful in ␣␤␦ receptors. For instance, ␦L9 T mutations produce small EC 50 shifts (<4-fold; our unpublished observations) and GABA concentration-responses using mixtures of mutant and wild type subunits do not support strong inferences about stoichiometry of expressed ␣␤␦ receptors [75] . Comparison of concatenated subunit assemblies to free ␣1/4␤2/3␦ receptors gives no "best match" result based on GABA EC 50 and neurosteroid enhancement of maximal GABA-induced currents [76, 77] . Both dimer (␤-␣) and trimer (␤-␣-␥ or ␤-␣-␦) can form functional receptors alone. In ␣␤␥ receptors, the current amplitude resulting from ␤-␣-␥ and ␤-␣ coexpression is much bigger than that of receptors formed from either dimer or trimer alone. Thus, it is evident that pentameric ␤-␣-␥/␤-␣ receptor currents dominate when both dimer and trimer are co-expressed [74] . However, in ␣␤␦ receptors, the current amplitude resulting from co-expression of ␤-␣-␦ and ␤-␣ is similar to that from receptors formed from either dimer or trimer alone. Thus, it is uncertain if pentameric ␤-␣-␦/␤-␣ receptors are the predominant form when both dimer and trimer are co-expressed. Moreover, ␣4␤2␦ receptors display very different neurosteroid activation efficacy relative to GABA in oocytes and HEK cells, although results in the two cell types agree better when ␤2-␦ concatemers are coexpressed with free ␣4 subunits. This implies that free subunits assemble differently in the two cell types [45] .
Spontaneous activity is not observed in recombinant ␣1␤2␦ receptors, but has been reported in ␣4␤3␦ and ␣6␤2␦ receptors [78, 79] . Maximally activating GABA concentrations evoke peak currents from recombinant ␣␤␦ receptors that are enhanced over 20-fold by positive allosteric modulators [59, 64, 80, 81] . These observations led us to estimate that saturating GABA concentrations activate only 3-5% of ␣1␤3␦ receptors [46] . ␣4/6␤2/3␦ receptors are very sensitive to GABA, with GABA EC 50 less than 1 M [64, 80, 82] . Neuronal tonic currents appear to be nondesensitizing even with addition of exogenous GABA [83] , and ␣1␤2/3␦ receptors activated by maximal GABA exhibit very little or no desensitization [58, 59, 84] . Although ␣4␤2/3␦ and ␣6␤3␦ receptors desensitize in response to >1 mM GABA [64, 67, 80, 85] , the rate is slower than in ␣4␤3␥2 and ␣6␤3␥2 receptors [65, 85] . Deactivation of ␣␤␦ receptors is faster than that of ␣␤␥ receptors, consistent with low GABA efficacy.
In some recombinant expression systems, ␦ subunits may not efficiently incorporate into ternary ␣␤␦ receptors [46, [86] [87] [88] . This likely explains why one study found identical general anesthetic modulation in both ␣4␤3␦ and ␣4␤3 receptors [89] . The subunit stoichiometry of surface ␣␤␦ receptors apparently depends on the ratios of ␣:␤:␦ mRNAs or cDNAs used for heterologous expression [72, 88, 90, 91] . By varying the subunit ratios and the concentrations of mRNAs injected into oocytes, we observed that increasing the ␦ subunit ratio (␣:␤:␦ ratio = 1:1:3) and reducing total injected mRNA (10-fold from the 5 ng/oocyte typically used for ␣1␤␥2 receptors) maximized current enhancement by allosteric modulators, suggesting optimal incorporation of the ␦ subunit into ␣1␤3␦ receptors [46] . It is unknown if this approach can be used to monitor the incorporation of the ␦ subunit into ␣4␤␦ and ␣6␤␦ receptors. In expression studies of ␣1␤2␦ in HEK cells, 10-fold less ␦ subunit cDNA is required to eliminate the functional signature of ␣1␤2 receptors [72] . Thus, consistent incorporation of ␦ subunit into heterologously expressed receptors requires close attention to experimental conditions.
Functional effects of anesthetics on synaptic ␣␤␥ GABA A receptors
Many potent general anesthetics allosterically enhance the activation of GABA A receptors [7, [92] [93] [94] [95] . In studies of phasic inhibition associated with ␣␤␥ receptors, etomidate [96, 97] , propofol [98, 99] , the barbiturate pentobarbital [100, 101] , and the neurosteroids tetrahydrodeoxycorticosterone (THDOC) [102] and alphaxalone [103] all prolong IPSC decay. Potent general anesthetics also enhance GABA-evoked activation of oocyte-expressed ␣1␤2/3␥2 receptors (Fig. 2B) , producing large "leftward shifts" (decreased EC 50 ) and a small "upward shift" (increased maximal GABA current response) in concentration-responses [46, 60, 69, 104, 105] . This pattern of anesthetic-induced changes indicates high GABA intrinsic efficacy in ␣␤␥ receptors, consistent with previous single channel studies [59, 106, 107] . At high concentrations, general anesthetics also directly activate ␣␤␥ receptors (GABA-independent activation or allosteric agonism) [7] . Both positive modulation of orthosteric agonist responses and direct receptor activation by the anesthetic etomidate display similar pharmacological characteristics [57, 108, 109] . In ␣1␤3␥2 receptors, the direct effect of pentobarbital appears bi-phasic, with maximal currents due to direct agonism at ∼1 mM and inhibition at higher concentrations via a distinct inhibitory site [59] .
In rapid kinetic studies of ␣1␤3␥2 receptors, pentobarbital, propofol and THDOC do not alter or slightly reduce peak currents evoked by maximal GABA [58, 59, 64] . Pentobarbital and propofol decrease the extent of desensitization of ␣1␤3␥2 and/or ␣6␤3␥2 receptors [49, 59, 64] , while THDOC and etomidate do not alter desensitization of ␣1␤2/3␥2 receptors [58, 66] . General anesthetics prolong the deactivation of ␣1␤2/3␥2 and/or ␣6␤3␥2 receptors [58, 59, 64, 66] . Thus, desensitization may contribute to the differences in apparent maximal intrinsic efficacy of GABA in ␣␤␥ receptors studied in Xenopus oocytes vs. HEK293 cells.
Functional effects of anesthetics on extrasynaptic ␣␤␦ GABA A receptors
Extrasynaptic ␣␤␦ receptors are also important targets for general anesthetics [7] , which enhance tonic currents in multiple brain regions [41, 42, 83, 98, [110] [111] [112] [113] [114] [115] [116] [117] . General anesthetics alter GABAdependent responses in oocyte-expressed ␣␤␦ receptors (Fig. 2C) by inducing a small "leftward shift" and a large "upward shift", contrasting with the pattern in ␣␤␥ receptors [46, 81] . The large increase in maximal GABA currents indicates low GABA intrinsic efficacy in ␣␤␦ receptors. Consistent with this, single channel recordings in the presence of high GABA show smaller mean channel open times in ␣␤␦ than in ␣␤␥ receptors [58, 59, 106, 118, 119] . Application of general anesthetics with maximal GABA increases the mean channel open time by inducing long-lived open states in ␣1␤3␦ receptors in single channel recordings [58, 59, 68, 119] . General anesthetics at high concentration also directly activate ␣␤␦ receptors. Pentobarbital alone directly activates ␣1␤3␦ receptors, with maximal responses at ∼3 mM [59] .
Artificial synapse experiments also show that general anesthetics substantially enhance peak currents of ␣1␤3␦ or ␣4␤3␦ receptors expressed in HEK cells [44, 58, 59, 64, 85, 89, 120] . Propofol and THDOC appear to evoke a greater augmentation of maximal GABA currents in ␣1␤3␦ than in ␣4/6␤3␦ receptors [58, 64, 76, 85, 89] . Different anesthetics evoke variable changes in ␣␤␦ receptor desensitization. Etomidate reduces the extent of desensitization for ␣1␤3␦ receptors [44] . This effect contrasts with studies showing apparent acceleration of ␣1␤3␦ receptor desensitization by both pentobarbital and THDOC [49, 58, 59 ]. Propofol does not alter desensitization of either ␣1␤3␦ or ␣6␤3␦ receptors [64] . Etomidate, pentobarbital and THDOC prolong deactivation of ␣1␤3␦ receptor currents [44, 49, 58, 59] . Propofol prolongs the deactivation of ␣6␤3␦ receptors but not ␣1␤3␦ receptors [64] .
Endogenous neurosteroids are mainly synthesized in glial cells [121, 122] , and their concentrations in the brain (10-300 nM) are dynamically regulated [123, 124] . The endogenous neurosteroid THDOC at physiological concentrations selectively enhances tonic currents mediated by ␣␤␦ receptors [83] . Both expression and function of ␣␤␦ receptors change with fluctuating neurosteroid levels in rodent brain [125] [126] [127] [128] [129] [130] . Sensitivity of tonic GABAergic currents to neurosteroid modulation varies among brain regions. In hippocampus, 10 nM THDOC reduces neuronal excitability by augmenting tonic ␣␤␦ receptor currents [83] . In thalamocortical neurons, although 100 nM THDOC enhances tonic currents, 10 nM THDOC does not [42] .
Several factors likely contribute to region-specific modulation of tonic inhibition by neurosteroids: First, the distribution of GABA A receptors in the brain is heterogeneous [8, 9] . The major ␣␤␦ receptor subtype expressed in thalamus is ␣4␤␦, while ␣1␤␦ subtype is undetectable [20, 21] . In contrast, the hippocampus expresses both ␣4␤␦ and ␣1␤␦ receptors [22, 24] . ␣4␤␦ and ␣1␤␦ receptors exhibit differential sensitivity both to GABA [59, 80, 82] and to neurosteroids (see above). Second, the different effects of neurosteroids on tonic inhibition in the hippocampus and thalamus may be partly due to phosphorylation of ␣␤␦ receptors. The function and modulatory effect of ␣4␤3␦ receptors are regulated by both PKA and PKC [79, [131] [132] [133] .
Shift analysis using an allosteric co-agonist model
A Monod-Wyman-Changeux (MWC) allosteric model was introduced by Chang & Weiss to describe the activation of wild type and gating mutant ␣1␤2␥2 receptors [134] . In this model, estimated open probability (P open ) in a population of receptors is calculated by adding normalized spontaneous receptor activity to activated currents and correcting for the intrinsic efficacy of GABA. GABA efficacy is estimated by measuring how much maximal GABA currents are enhanced by strong positive modulators such as anesthetics or neurosteroids. MWC models allow and account for spontaneous channel activity, and were shown to account for effects on both GABA EC 50 and spontaneous activation associated with L9 S mutations [134] .
The effects of general anesthetics on ␣␤␥ receptor function are similar to those of L9 S gating mutations [134] . The combined effects of GABA and anesthetics, including etomidate, propofol, and pentobarbital, can be quantitatively accounted for using MWC coagonist models (Fig. 4) [60, 104, 135, 136] . Because MWC models explicitly account for agonist intrinsic efficacy, MWC shift analysis also unifies leftward-shift, increased maximal response, and direct anesthetic activation to quantify anesthetic modulation in different GABA A receptor subtypes [46, 136] or when a partial orthosteric agonist is combined with an anesthetic [135] . We modeled the allosteric modulation of etomidate on ␣1␤3␦ receptors using an MWC model that accounted for all of above effects when normal- ized responses were corrected for the low intrinsic efficacy of GABA in these receptors [46] .
Our MWC models are based on data collected from oocyte recordings and do not include desensitized states. As the solution exchange times are slow in oocyte recordings, fast components of desensitization are obscured. However, MWC models that include desensitized states are consistent with the kinetics of patch-clamp recordings obtained with rapid solution exchange [137] .
Structural identification of selective anesthetic sites on synaptic ␣␤␥ GABA A receptors
Multiple approaches have been used to locate general anesthetic sites on GABA A receptors, revealing evidence of remarkable site selectivity for some drugs. Both photolabeling and chimera strategies are unbiased approaches that can locate potential sites, while approaches based on point mutations can provide hypothesisbased complementary evidence. Each of these approaches has multiple limitations and weaknesses. Here, we briefly review these approaches and how they have contributed to identifying GABA A receptor sites for four potent anesthetics.
Chimeric constructs and point mutations
Chimeric constructs and point mutations have long been used to evaluate structure-function relationships of general anesthetics and other GABA A receptor modulators [138] [139] [140] [141] . However, these studies have limited value in identifying drug contacts. Chimeric approaches have proven useful in cases where two homologous subunits display widely different drug sensitivities. For example, differential etomidate sensitivity in GABA A receptors containing ␤1 vs. ␤2 led to identification of the M2-15 residue (␤1S265 vs. ␤2N265) as key residues. However, care must be taken in evaluating efficacy and potency metrics-a set of ␤3/1 chimeras that were constructed to locate pentobarbital sites showed varying effects on pentobarbital agonism vs. maximal GABA effects, but variance and single channel analyses indicated that GABA efficacy was altered without affecting pentobarbital efficacy [142] . In the case of point mutations, we tested whether the etomidate-insensitive phenotype of ␣1M236W and ␤2M286W mutations was generalizable to other anesthetic-photolabeled residues, and found that Trp mutations do not reliably identify drug contact vs. non-contact residues [143] .
Photolabeling
Photolabeling has provided unbiased regional identification of anesthetic binding sites on GABA A receptors [3, 94, 144] . However, many of these studies used GABA A receptors with only one or two subunit isotypes (e.g. ␤3 or ␣1␤3) instead of the most common ␣1␤2/3␥2 construct. These models limit data analysis and comparisons with functional studies [35, 145] . More generally, photoreactive groups, if appended to parent drug molecular structures in key binding regions, may disrupt pharmacological activity. Thus, photolabeling with many anesthetic derivatives likely fails to identify important contact residues.
Substituted cysteine accessibility modification-protection (SCAMP)
Substituted cysteine accessibility modification-protection (SCAMP) was first used by Bali and Akabas to test propofol interactions in GABA A receptors [146] and applied more extensively by us to identify contact sites for multiple anesthetics [35] . SCAMP involves mutation of a putative anesthetic contact residue to cysteine, introducing a free sulfhydryl. Formation of covalent bond formation after exposure to a sulfhydryl-reactive chemical agent is detected with electrophysiology. If the cysteine-substitution is in an anesthetic binding pocket, drugs occupying the site should reduce the rate of covalent bond formation through steric competition [35] . Our recent analysis shows that SCAMP results agree with photolabeling results, indicating that SCAMP is a reliable technique to identify new contact residues [143] . In SCAMP experiments, it is also important to demonstrate drug-specific effects on cysteine modification. If all anesthetics similarly affect cysteine modification rate, this may indicate an allosteric rather than a steric interaction [35] .
Etomidate
Etomidate is a potent stereoselective imidazole ester anesthetic. R-(+)-etomidate positively modulates and directly activates ␣1␤2␥2 receptors about 20-fold more potently than S-(−)-etomidate, similar to the relative anesthetic potency of etomidate enantiomers in animals [147] . Heterologous ␣␤␥ receptors with ␤2 or ␤3, but not ␤1 are modulated by etomidate [109] . This observation led to chimera and point mutant studies that identified an asparagine residue (N265) in the M2 helices of ␤2 or ␤3 subunits as a major determinant of etomidate sensitivity [108, 148] . Quantitative MWC co-agonist modeling of etomidate effects in ␣1␤2␥2 receptors indicated the presence of two equivalent sites [135] . MWC analysis of etomidate effects in ␣1␤2N265S␥2 and ␣1␤2N265M␥2 receptors suggested effects on drug binding to open-channel states more than closed states [69] . Photoreactive etomidate derivatives incorporate at ␣1M236 in ␣-M1 and ␤M286 in ␤-M3, which are located in structural models at transmembrane ␤ + /␣ − interfaces [149, 150] . Tryptophan mutations at either ␣1M236 or ␤2M286 induce spontaneously active GABA-sensitive receptors that are weakly modulated by etomidate, suggesting that the Trp side chains both mimic etomidate binding and occlude the sites [151] . Concatemeric subunit ␤2-␣1 and ␤2-␣1-␥2 assemblies with ␣1M236W mutations produce equivalent functional changes in expressed receptors, supporting equivalence of the two etomidate sites [74] . Photolabeling also indicated etomidate binding at ␤3 + /␤3 − interfaces in ␣1␤3 receptors [152] , accounting for etomidate activation of ␤3 homomeric receptors [153] . SCAMP has mapped additional etomidate contact residues in ␣1␤2/3␥2 receptors [143, 154] , all of which map to transmembrane ␤ + /␣ − interfaces.
In summary, there is abundant evidence that etomidate binds selectively in the two ␤ + /␣ − interfaces of ␣1␤2/3␥ GABA A receptors.
barbituric acid (R-mTFD-MPAB) was developed as a barbiturate photolabel that was found to be both potent and stereoselective in ␣1␤2/3␥2 receptors and in animals [155] . Photolabeling reveals that it binds specifically at transmembrane subunit interfaces between ␥2-M3 and ␤3-M1 (␥ + /␤ − ) and between ␣1-M3 and ␤3-M1 (␣ + /␤ − ) helices in ␣1␤3␥2 receptors [156] . SCAMP studies have confirmed some of these contact residues in ␣1␤3␥2 receptors and identified additional contacts [143] . The convulsant barbiturate photolabel S-1-methyl-5-propyl-5-(mtrifluoromethyl-diazirynylphenyl) barbituric acid (S-mTFD-MPPB) inhibits the function of ␣1␤3␥2 receptors [157, 158] , and also incorporates at ␥ + /␤ − interfaces on ␣1␤3␥2 receptors [159] . This suggests that the ␥ + /␤ − interface can mediate allosteric channel gating shifts in opposing directions, perhaps depending on the specific orientation of hypnotic vs. convulsant barbiturates within the site.
In summary, m-substituted MPAB and MPPB derivatives selectively bind in ␣ + /␤ − and ␥ + /␤ − interfaces of ␣1␤2/3␥2 receptors. Studies are underway to establish if mutations in these sites display asymmetrical functional effects.
Propofol
Propofol contacts were tentatively identified in mutant studies at ␤2M286 in ␤2-M3 [160] . MWC shift analysis indicates that propofol possesses more than two allosteric sites on ␣1␤2␥2 receptors [104] . In line with this prediction, photolabeling studies demonstrated that propofol binds at ␤ + /␣ − and ␣ + /␤ − interfaces in ␣1␤3 receptors, which are homologues of the inter-subunit sites for both etomidate and R-mTFD-MPAB, respectively [35, 161] . Mutant studies support this conclusion [141] . Thus, propofol shares binding sites with both etomidate and barbiturates. Photolabeling in ␤3 homomeric and ␣1␤3 receptors also suggested propofol contact with ␤3H267 [162] , and ␤3H267 may be close to the sites for RmTFD-MPAB [163] . However, studies using mutational analysis and SCAMP techniques do not support the idea that ␤3H267 contacts propofol [163, 164] .
Neurosteroids
Neurosteroids bind in sites that are distinct from those where etomidate, propofol, and barbiturates bind based on functional and photolabeling results. Neurosteroids enhance GABA A receptor activation by etomidate and barbiturates, synergize with etomidate in anesthetizing animals [165] , and enhance photolabeling by etomidate analogs [166] . Photolabeling in ␤3 homomeric receptors identified F301 in ␤3-M3 as a possible neurosteroid binding site [167] . Recent published data supports the hypothesis that neurosteroid enhancing sites are located in ␤ + /␣ − interfaces near the inner end of ␤-M3 and ␣-M1 helices. Crystal structures of homomeric chimeric channels that include ␣ subunit transmembrane domains reveal THDOC interactions with ␣Q242 [168, 169] , a site where mutations significantly alter neurosteroid sensitivity [170, 171] . Possible neurosteroid contact residues in ␣1␤2␥2 receptors include S241 and Q242 in ␣1-M1 and N407 and Y410 in ␣1-M4 [170] [171] [172] [173] . SCAMP experiments comparing contacts for propofol, etomidate and alphaxalone on ␤3-M3 in ␣1␤3␥2 receptors show that alphaxalone protects cysteine substitutions at ␤3 residues V290, F293, L297 and F301, and some of these mutations also reduce neurosteroid sensitivity [174] . In addition, SCAMP studies confirm that neurosteroids do not interact with established etomidate and RmTFD-MPAB contacts [105] . Neurosteroid sites are thus adjacent and intracellular to the sites where etomidate binds in ␤ + /␣ − interfaces, and the effects of mutations in these sites suggest that they account for the majority of neurosteroid effects on channel gating.
General anesthetics as structural probes in ␣␤␦ GABA A receptors
Chimera studies have aimed at identifying the structures underlying the differential patterns of general anesthetic modulation in ␣␤␥ vs. ␣␤␦ receptors. For example, general anesthetics strongly enhance the peak currents of ␣1␤3␦ receptors but only slightly potentiate ␣1␤3␥2 currents in the presence of saturating GABA [49, 58] . Feng and Macdonald [49] compared pentobarbital effects in receptors containing ␥2/␦ or ␦/␥2 subunit chimeras vs. wild type ␣1␤3␥2 and ␣1␤3␦ receptors. The relative efficacy of pentobarbital vs. GABA depended on ␦ sequences between the N-terminus and the middle of M1. However, GABA efficacy in the chimeric receptors was not assessed, so it remains uncertain whether the chimeras affected GABA efficacy, pentobarbital efficacy, or both. It is also possible that the chimeras affected subunit assembly.
The formalism of MWC allosteric models requires assessment of GABA efficacy and thus establishes a stronger framework for functional analysis of structural changes. Taking advantage of the unique binding sites of etomidate on ␣␤␥ GABA A receptors, we inferred if putative ␣␤␦ receptors possess the same ␤ + /␣ − interfaces by quantifying the allosteric modulation of these two receptor isoforms by etomidate using MWC allosteric model. Our hypothesis was that if the stoichiometry and subunit arrangement of ␣1␤3␥2 and ␣1␤3␦ receptors are different, the number of etomidate binding sites on both receptor isoforms would be different, which would result in divergent allosteric effects of etomidate [46] . We observed that etomidate at 3.2 M produced a 10-fold leftward shift and 24% upward shift of GABA concentration-responses in ␣1␤3␥2 receptors. However, the same concentration of etomidate evoked a 3-fold leftward shift and a 17-fold upward shift of GABA concentrationresponses in ␣1␤3␦ receptors [46] . We quantitatively compared etomidate (3.2 M) modulation of GABA-dependent activation in ␣1␤3␥2 vs. ␣1␤3␦ receptors using MWC model analysis. Even though etomidate effects on GABA-dependent responses are very different in ␣1␤3␥2 vs. ␣1␤3␦ receptors, after correcting data for the different GABA efficacies in these two receptors, our analysis indicated comparable allosteric shifts [46] . Comparable allosteric modulation of ␣4␤2␥2 and ␣4␤2␦ receptors by alfaxalone was also observed using the similar approach [175] . Moreover, because etomidate selectively acts via two ␤ + /␣ − interfacial sites in ␣1␤3␥2 receptors [35] , this result may indicate that ␣1␤3␦ receptors also contain two ␤ + /␣ − interfaces. If this is the case, our data tend to support previous studies that ␦ simply replaces ␥ in the established synaptic subunit arrangement [72, 75, 88, 176] . These data also agree with a previous observation that pentobarbital evokes similar modulation in both ␣1␤3␦ and ␣1␤3␥2 currents activated with low GABA concentrations [59] . Indeed, synaptic ␣␤␥ receptors may contribute significantly to modulation of tonic currents by general anesthetics [177] .
Using site-selective anesthetics is also advantageous in studying GABA A receptors formed from subunit concatemers. THDOC was used as a probe drug to seek information about receptor subunit arrangement of free ␣1/6␤3␦ receptors vs. various concatenated ␣1/6␤3␦ receptors [50, 76] . It was proposed that free ␣1␤3␦ receptors may display at least three subunit arrangements: ␤3-␣1-␦-␤3-␣1, ␤3-␣1-␦-␣1-␤3 and ␣1-␤3-␣1-␤3-␦ (Fig. 3B-D ) [76] . We further examined the allosteric modulation of concatenated ␤3-␣1-␦/␤3-␣1 receptors (formed by injection of ␤3-␣1-␦ trimer and ␤3-␣1 dimer mRNAs in oocytes) by etomidate at 3.2 M and found that etomidate produced a 3-fold leftward shift and a 14-fold upward shift of GABA concentration-responses [46] . We quantitatively compared etomidate modulation of free ␣1␤3␦ receptors and concatenated ␤3-␣1-␦/␤3-␣1 receptors, and found close agreement, further supporting the ␤3-␣1-␦-␤3-␣1 subunit arrangement for oocyte-expressed ␣1␤3␦ receptors (Fig. 3B) [46] . However, it should be noted that our data do not determine the definite stoichiometry and subunit arrangement of ␣1␤3␦ receptors. For example, it is possible that etomidate may bind to other intersubunit sites in ␣1␤3␦ receptors, such as ␦ + /␣ − or ␤ + /␤ − interface, which may exert similar allosteric effect to those ␤ + /␣ − sites. R-mTFD-MPAB acts in ␣␤␥ receptors via both ␣ + /␤ − and ␥ + /␤ − sites, but its effects in ␣␤␦ receptors remain unexplored. We measured allosteric modulation by R-mTFD-MPAB in free and concatenated ␤3-␣1/␤3-␣1-␦ receptors and found them to be similar (unpublished observations). Further mutant studies to compare the contributions of ␣ + /␤ − sites vs. ␦ + /␤ − sites and other possible interfacial sites are needed to strengthen our conclusion.
Photolabeling with site-selective anesthetics provides additional insight into ␣␤␦ receptor subunit arrangements. Chiara et al. [178] identified azi-etomidate and R-mTFD-MPAB incorporation sites in human ␣4␤3␦ receptors that were expressed in HEK cells and purified in detergent. Neither photolabel incorporated into the ␦ subunit. Azi-etomidate incorporated in ␤3M286 (M3) and ␣4M269 (M1), consistent with ␤ + /␣ − sites. Both photolabels incorporated at ␤3M227 (M1), suggesting anesthetic sites in ␤3 + /␤3 − interfaces. Assuming homogeneous assembly, possible subunit assemblies are ␤3-␤3-␦-␤3-␣4 or ␤3-␤3-␣4-␦-␣4 (Fig. 3E,  F) [178] . If ␣1␤3␦ receptors share similar stoichiometry and subunit arrangement with ␣1␤3␥2 receptors, these data suggest that the stoichiometry and subunit arrangement of ␣4␤3␦ receptors may be different from those of ␣1␤3␦ receptors.
In summary, anesthetics, particularly etomidate, neurosteroids and R-mTFD-MPAB that display strong specificity for certain subunit interfacial sites, are informative structural probes for heteromeric GABA A receptors. Some of these drugs apparently can also act via ␤ + /␤ − interfaces, requiring chimera studies to test inferences. Propofol acts via four sites per ␣␤␥ receptor, and is thus of no value as a probe of ␣␤␦ receptor subunit arrangements. Interpretation of anesthetic functional effects must include independent assessment of GABA efficacy, and formal MWC model analyses enforce this, while also enabling quantitative comparisons of drug effects in different receptor isoforms.
Conclusions
The structure of neuronal ␣␤␦ receptors remains uncertain, and the structure of expressed recombinant ␣␤␦ receptors may vary with cell type and other variables. Because certain general anesthetics act at well-defined ␣␤␥ subunit interfaces, they and subunit modifications that affect anesthetic sensitivity in ␣␤␥ receptors represent useful tools for probing the subunit arrangement of ␣␤␦ receptors. As we learn more about anesthetic binding sites, the value of these tools as structural probes will also grow.
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